{"id":5085,"date":"2011-12-01T09:00:00","date_gmt":"2011-12-01T09:00:00","guid":{"rendered":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/positieve-resultaten-vor-behandeling-met-diaprep277\/"},"modified":"2024-09-23T11:22:47","modified_gmt":"2024-09-23T11:22:47","slug":"positieve-resultaten-vor-behandeling-met-diaprep277","status":"publish","type":"post","link":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/positieve-resultaten-vor-behandeling-met-diaprep277\/","title":{"rendered":"Positieve resultaten voor behandeling met DiaPep277"},"content":{"rendered":"Andromeda Biotech heeft positieve resultaten gemeld over een fase 3 klinisch onderzoek naar behandeling van T1D met DiaPrep277, een beoogd nieuw geneesmiddel voor immuuntherapie.\n\nBij de productie van insuline in beta cellen ontstaat een bijproduct, het C-peptide. Meting van de C-peptide niveaus is dus een goede indicator voor de resterende insuline productie in de pancreas. In het onderzoek werden met DiaPrep277 behandelde pati\u00ebnten vergeleken met een controlegroep. Na verloop van tijd hadden de behandelde pati\u00ebnten duidelijk betere C-peptide niveaus dan de controlegroep. Ook bleken ze beter in staat om hun bloedglucose niveaus zelf te handhaven.\n\nEr werden geen belangrijke bijwerkingen van DiaPrep277 gevonden.\n\nEen wereldwijd fase 3 onderzoek met 450 pati\u00ebnten gaat medio 2012 van start in 120 medische centra verspreid over de VS, Canada, Europa, Isra\u00ebl en Argentini\u00eb.\n\n<a href=\"http:\/\/asweetlife.org\/a-sweet-life-staff\/in-the-news\/type-1-in-the-news\/positive-results-for-diapep277-type-1-diabetes-treatment-in-phase-3-study\/22339\/\">Lees verder <\/a>(Engelstalig)","protected":false,"raw":""},"excerpt":{"rendered":"<p>Andromeda Biotech heeft positieve resultaten gemeld over een fase 3 klinisch onderzoek naar behandeling van T1D met DiaPrep277, een beoogd nieuw geneesmiddel voor immuuntherapie. Bij de productie van insuline in beta cellen ontstaat een bijproduct, het C-peptide. Meting van de C-peptide niveaus is dus een goede indicator voor de resterende insuline productie in de pancreas. [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[184,188],"tags":[],"class_list":["post-5085","post","type-post","status-publish","format-standard","hentry","category-archief","category-genezen"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.3 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Positieve resultaten voor behandeling met DiaPep277 - Breakthrough T1D<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/positieve-resultaten-vor-behandeling-met-diaprep277\/\" \/>\n<meta property=\"og:locale\" content=\"nl_NL\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Positieve resultaten voor behandeling met DiaPep277 - Breakthrough T1D\" \/>\n<meta property=\"og:description\" content=\"Andromeda Biotech heeft positieve resultaten gemeld over een fase 3 klinisch onderzoek naar behandeling van T1D met DiaPrep277, een beoogd nieuw geneesmiddel voor immuuntherapie. Bij de productie van insuline in beta cellen ontstaat een bijproduct, het C-peptide. Meting van de C-peptide niveaus is dus een goede indicator voor de resterende insuline productie in de pancreas. [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/positieve-resultaten-vor-behandeling-met-diaprep277\/\" \/>\n<meta property=\"og:site_name\" content=\"Breakthrough T1D\" \/>\n<meta property=\"article:published_time\" content=\"2011-12-01T09:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-09-23T11:22:47+00:00\" \/>\n<meta name=\"author\" content=\"ylt-admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Geschreven door\" \/>\n\t<meta name=\"twitter:data1\" content=\"ylt-admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Geschatte leestijd\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minuut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/positieve-resultaten-vor-behandeling-met-diaprep277\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/positieve-resultaten-vor-behandeling-met-diaprep277\/\"},\"author\":{\"name\":\"ylt-admin\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/c141fde9814deb17e9eb392bdb6619a6\"},\"headline\":\"Positieve resultaten voor behandeling met DiaPep277\",\"datePublished\":\"2011-12-01T09:00:00+00:00\",\"dateModified\":\"2024-09-23T11:22:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/positieve-resultaten-vor-behandeling-met-diaprep277\/\"},\"wordCount\":138,\"publisher\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#organization\"},\"articleSection\":[\"Archief\",\"Genezen\"],\"inLanguage\":\"nl-NL\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/positieve-resultaten-vor-behandeling-met-diaprep277\/\",\"url\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/positieve-resultaten-vor-behandeling-met-diaprep277\/\",\"name\":\"Positieve resultaten voor behandeling met DiaPep277 - Breakthrough T1D\",\"isPartOf\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#website\"},\"datePublished\":\"2011-12-01T09:00:00+00:00\",\"dateModified\":\"2024-09-23T11:22:47+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/positieve-resultaten-vor-behandeling-met-diaprep277\/#breadcrumb\"},\"inLanguage\":\"nl-NL\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/positieve-resultaten-vor-behandeling-met-diaprep277\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/positieve-resultaten-vor-behandeling-met-diaprep277\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/breakthrought1d.eu\/nl\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Positieve resultaten voor behandeling met DiaPep277\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#website\",\"url\":\"https:\/\/breakthrought1d.eu\/nl\/\",\"name\":\"Breakthrough T1D\",\"description\":\"Wij zetten ons in voor een toekomst zonder T1D\",\"publisher\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/breakthrought1d.eu\/nl\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"nl-NL\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#organization\",\"name\":\"Breakthrough T1D\",\"url\":\"https:\/\/breakthrought1d.eu\/nl\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2024\/11\/BTlogo.png\",\"contentUrl\":\"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2024\/11\/BTlogo.png\",\"width\":330,\"height\":141,\"caption\":\"Breakthrough T1D\"},\"image\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/c141fde9814deb17e9eb392bdb6619a6\",\"name\":\"ylt-admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/67a3317a8082bc0f586c2e46f82a1617530cf674f2027a1a7d60fdff63a2c3e8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/67a3317a8082bc0f586c2e46f82a1617530cf674f2027a1a7d60fdff63a2c3e8?s=96&d=mm&r=g\",\"caption\":\"ylt-admin\"},\"sameAs\":[\"https:\/\/87.250.144.92\"],\"url\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/author\/ylt-admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Positieve resultaten voor behandeling met DiaPep277 - Breakthrough T1D","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/positieve-resultaten-vor-behandeling-met-diaprep277\/","og_locale":"nl_NL","og_type":"article","og_title":"Positieve resultaten voor behandeling met DiaPep277 - Breakthrough T1D","og_description":"Andromeda Biotech heeft positieve resultaten gemeld over een fase 3 klinisch onderzoek naar behandeling van T1D met DiaPrep277, een beoogd nieuw geneesmiddel voor immuuntherapie. Bij de productie van insuline in beta cellen ontstaat een bijproduct, het C-peptide. Meting van de C-peptide niveaus is dus een goede indicator voor de resterende insuline productie in de pancreas. [&hellip;]","og_url":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/positieve-resultaten-vor-behandeling-met-diaprep277\/","og_site_name":"Breakthrough T1D","article_published_time":"2011-12-01T09:00:00+00:00","article_modified_time":"2024-09-23T11:22:47+00:00","author":"ylt-admin","twitter_card":"summary_large_image","twitter_misc":{"Geschreven door":"ylt-admin","Geschatte leestijd":"1 minuut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/positieve-resultaten-vor-behandeling-met-diaprep277\/#article","isPartOf":{"@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/positieve-resultaten-vor-behandeling-met-diaprep277\/"},"author":{"name":"ylt-admin","@id":"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/c141fde9814deb17e9eb392bdb6619a6"},"headline":"Positieve resultaten voor behandeling met DiaPep277","datePublished":"2011-12-01T09:00:00+00:00","dateModified":"2024-09-23T11:22:47+00:00","mainEntityOfPage":{"@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/positieve-resultaten-vor-behandeling-met-diaprep277\/"},"wordCount":138,"publisher":{"@id":"https:\/\/breakthrought1d.eu\/nl\/#organization"},"articleSection":["Archief","Genezen"],"inLanguage":"nl-NL"},{"@type":"WebPage","@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/positieve-resultaten-vor-behandeling-met-diaprep277\/","url":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/positieve-resultaten-vor-behandeling-met-diaprep277\/","name":"Positieve resultaten voor behandeling met DiaPep277 - Breakthrough T1D","isPartOf":{"@id":"https:\/\/breakthrought1d.eu\/nl\/#website"},"datePublished":"2011-12-01T09:00:00+00:00","dateModified":"2024-09-23T11:22:47+00:00","breadcrumb":{"@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/positieve-resultaten-vor-behandeling-met-diaprep277\/#breadcrumb"},"inLanguage":"nl-NL","potentialAction":[{"@type":"ReadAction","target":["https:\/\/breakthrought1d.eu\/nl\/nieuws\/positieve-resultaten-vor-behandeling-met-diaprep277\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/positieve-resultaten-vor-behandeling-met-diaprep277\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/breakthrought1d.eu\/nl\/"},{"@type":"ListItem","position":2,"name":"Positieve resultaten voor behandeling met DiaPep277"}]},{"@type":"WebSite","@id":"https:\/\/breakthrought1d.eu\/nl\/#website","url":"https:\/\/breakthrought1d.eu\/nl\/","name":"Breakthrough T1D","description":"Wij zetten ons in voor een toekomst zonder T1D","publisher":{"@id":"https:\/\/breakthrought1d.eu\/nl\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/breakthrought1d.eu\/nl\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"nl-NL"},{"@type":"Organization","@id":"https:\/\/breakthrought1d.eu\/nl\/#organization","name":"Breakthrough T1D","url":"https:\/\/breakthrought1d.eu\/nl\/","logo":{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/logo\/image\/","url":"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2024\/11\/BTlogo.png","contentUrl":"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2024\/11\/BTlogo.png","width":330,"height":141,"caption":"Breakthrough T1D"},"image":{"@id":"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/c141fde9814deb17e9eb392bdb6619a6","name":"ylt-admin","image":{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/67a3317a8082bc0f586c2e46f82a1617530cf674f2027a1a7d60fdff63a2c3e8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/67a3317a8082bc0f586c2e46f82a1617530cf674f2027a1a7d60fdff63a2c3e8?s=96&d=mm&r=g","caption":"ylt-admin"},"sameAs":["https:\/\/87.250.144.92"],"url":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/author\/ylt-admin\/"}]}},"_links":{"self":[{"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/posts\/5085","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/comments?post=5085"}],"version-history":[{"count":1,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/posts\/5085\/revisions"}],"predecessor-version":[{"id":7350,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/posts\/5085\/revisions\/7350"}],"wp:attachment":[{"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/media?parent=5085"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/categories?post=5085"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/tags?post=5085"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}